So far, TK1 has been validated as a prognostic and predictive biomarker in BC patients only in serum; therefore, to the best of our knowledge, no tissue TK1 cut-off value with prognostic or predictive impact is present in the literature. The gene discussed is TK1; the disease is breast cancer.